Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Synaptic develops selective human alpha1A-receptor antagonists

Feb. 2, 1998

RTX enters phase II for urge incontinence

Jan. 27, 1998

FDA accepts RenaGel NDA for filing

Jan. 22, 1998

New urinary incontinence product from Biomatrix cleared for clinical trials

Jan. 12, 1998

Synaptic, Merck & Co. extend BPH research agreement

Jan. 5, 1998

Cephalon describes new indolocarbazoles for prostate disorders

Dec. 30, 1997

NDA filed for extended-release Ditropan formulation

Dec. 29, 1997

Bladder efficacy demonstrated for KATP channel opener

Dec. 19, 1997

Fujisawa describes preparation of new 5alpha-reductase inhibitor for BPH

Dec. 15, 1997

Sankyo isolates natural products for BPH

Nov. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.